Antianaerobe activity of RBX 7644 (ranbezolid), a new oxazolidinone, compared with those of eight other agents.
作者信息
Ednie Lois M, Rattan Ashok, Jacobs Michael R, Appelbaum P C
机构信息
Department of Pathology, Hershey Medical Center, Hershey, Pennsylvania 17033, USA.
出版信息
Antimicrob Agents Chemother. 2003 Mar;47(3):1143-7. doi: 10.1128/AAC.47.3.1143-1147.2003.
Abstract
The activity of ranbezolid (RBX 7644), a new oxazolidinone, against 306 anaerobes was compared with those of 11 other agents. The MICs at which 50% of the isolates tested are inhibited and those at which 90% of the isolates tested are inhibited (in micrograms per milliliter) were as follows: ranbezolid, 0.03 and 0.5; linezolid, 2 and 4; vancomycin, >16 and >16; teicoplanin, 1 and >16; quinupristin-dalfopristin, 1 and >8; amoxicillin-clavulanate, 0.5 and 2; imipenem, 0.125 and 1; clindamycin, 0.25 and 8; metronidazole, 1 and 4; gatifloxacin, 0.5 and 4; and moxifloxacin, 0.5 and 2, respectively. Ranbezolid had very good in vitro activity against both gram-negative and -positive anaerobes.
摘要
相似文献
1
Antianaerobe activity of RBX 7644 (ranbezolid), a new oxazolidinone, compared with those of eight other agents.
Antimicrob Agents Chemother. 2003 Mar;47(3):1143-7. doi: 10.1128/AAC.47.3.1143-1147.2003.
2
Anti-anaerobic activity of AZD2563, a new oxazolidinone, compared with eight other agents.
J Antimicrob Chemother. 2002 Jul;50(1):101-5. doi: 10.1093/jac/dkf088.
3
Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents.
Antimicrob Agents Chemother. 2003 Mar;47(3):1148-50. doi: 10.1128/AAC.47.3.1148-1150.2003.
4
Anti-anaerobic potential of ranbezolid: insight into its mechanism of action against Bacteroides fragilis.
Int J Antimicrob Agents. 2013 Jan;41(1):36-40. doi: 10.1016/j.ijantimicag.2012.09.013. Epub 2012 Nov 9.
5
Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species.
Antimicrob Agents Chemother. 2004 Nov;48(11):4430-4. doi: 10.1128/AAC.48.11.4430-4434.2004.
6
The growth-inhibitory properties of meropenem against anaerobes of clinical importance.
J Antimicrob Chemother. 1989 Sep;24 Suppl A:119-24. doi: 10.1093/jac/24.suppl_a.119.
7
Effect of oxazolidinone, RBx 7644 (ranbezolid), on inhibition of staphylococcal adherence to plastic surfaces.
J Chemother. 2008 Aug;20(4):420-7. doi: 10.1179/joc.2008.20.4.420.
8
Activity of linezolid against anaerobic bacteria.
Int J Antimicrob Agents. 2003 Jul;22(1):28-34. doi: 10.1016/s0924-8579(03)00087-6.
9
Synthesis and SAR of novel oxazolidinones: discovery of ranbezolid.
Bioorg Med Chem Lett. 2005 Oct 1;15(19):4261-7. doi: 10.1016/j.bmcl.2005.06.063.
10
In vitro activity of RBx 7644 (ranbezolid) on biofilm producing bacteria.
Int J Antimicrob Agents. 2004 Oct;24(4):369-73. doi: 10.1016/j.ijantimicag.2004.04.012.
引用本文的文献
1
Evaluating Effects of Antibiotics Across Preclinical Models of the Human Gastrointestinal Microbiota.
Microbiologyopen. 2025 Aug;14(4):e70030. doi: 10.1002/mbo3.70030.
2
Linezolid Resistance in Staphylococci.
Pharmaceuticals (Basel). 2010 Jun 24;3(7):1988-2006. doi: 10.3390/ph3071988.
3
Clinical and microbiological characteristics of Eggerthella lenta bacteremia.
J Clin Microbiol. 2015 Feb;53(2):626-35. doi: 10.1128/JCM.02926-14. Epub 2014 Dec 17.
4
Mode of action of Ranbezolid against staphylococci and structural modeling studies of its interaction with ribosomes.
Antimicrob Agents Chemother. 2009 Apr;53(4):1427-33. doi: 10.1128/AAC.00887-08. Epub 2008 Dec 15.
5
Moxifloxacin in the treatment of skin and skin structure infections.
Ther Clin Risk Manag. 2006 Dec;2(4):417-34. doi: 10.2147/tcrm.2006.2.4.417.
6
Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic species.
Antimicrob Agents Chemother. 2006 Mar;50(3):1112-7. doi: 10.1128/AAC.50.3.1112-1117.2006.
7
Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.
Drugs. 2005;65(5):695-724. doi: 10.2165/00003495-200565050-00007.
8
Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species.
Antimicrob Agents Chemother. 2004 Nov;48(11):4430-4. doi: 10.1128/AAC.48.11.4430-4434.2004.
9
In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections.
Antimicrob Agents Chemother. 2004 Mar;48(3):1012-6. doi: 10.1128/AAC.48.3.1012-1016.2004.
本文引用的文献
1
Anti-anaerobic activity of AZD2563, a new oxazolidinone, compared with eight other agents.
J Antimicrob Chemother. 2002 Jul;50(1):101-5. doi: 10.1093/jac/dkf088.
2
Comparative antianaerobic activity of BMS 284756.
Antimicrob Agents Chemother. 2001 Feb;45(2):589-92. doi: 10.1128/AAC.45.2.589-592.2001.
3
Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?
J Antimicrob Chemother. 2000 Sep;46(3):347-50. doi: 10.1093/jac/46.3.347.
4
Oxazolidinones: a review.
Drugs. 2000 Jan;59(1):7-16. doi: 10.2165/00003495-200059010-00002.
5
Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans.
Antimicrob Agents Chemother. 1999 Jun;43(6):1469-74. doi: 10.1128/AAC.43.6.1469.
6
The in-vitro activity of linezolid (U-100766) and tentative breakpoints.
J Antimicrob Chemother. 1998 Dec;42(6):721-8. doi: 10.1093/jac/42.6.721.
7
Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms.
Antimicrob Agents Chemother. 1998 Sep;42(9):2459-62. doi: 10.1128/AAC.42.9.2459.
8
Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam.
J Antimicrob Chemother. 1993 Aug;32(2):223-31. doi: 10.1093/jac/32.2.223.
9
Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers.
Antimicrob Agents Chemother. 1990 Aug;34(8):1546-50. doi: 10.1128/AAC.34.8.1546.
10
Characterization of beta-lactamases from non-Bacteroides fragilis group Bacteroides spp. belonging to seven species and their role in beta-lactam resistance.
Antimicrob Agents Chemother. 1990 Nov;34(11):2169-76. doi: 10.1128/AAC.34.11.2169.
Zotero 插件